アトピー性皮膚炎（AD）：疫学予測（～2033年）

当レポートでは、主要7市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）におけるアトピー性皮膚炎（AD）について調査分析し、ADの重症度、過去の疫学的動向に関する情報を提供しています。

目次

第1章 アトピー性皮膚炎：エグゼクティブサマリー

• カタリスト
• 関連レポート
• 今後のレポート

第2章 疫学

• 疾患の背景
• 危険因子と合併症
• 世界の過去の動向
• 主要7市場の予測手法
• ADの疫学的予測（2023年～33年）
  • 12ヶ月以内に診断されたADの患者数
  • 12ヶ月以内に診断されたADの患者数：年齢別
  • 12ヶ月以内に診断されたADの患者数：性別
  • 12ヶ月以内に診断されたADの患者数：重症度別
• 議論
  • 疫学的予測の考察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第3章 付録

List of Tables

• Table 1: Summary of updated data types
• Table 2: Risk factors and comorbidities for AD

List of Figures

• Figure 1: 7MM, 12-month diagnosed prevalent cases of AD, N, both sexes, all ages, 2023 and 2033
• Figure 2: 7MM, 12-month diagnosed prevalence of AD, %, all ages, 2023
• Figure 3: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of AD in the adult population
• Figure 4: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of AD in the pediatric population
• Figure 5: 7MM, sources used to forecast the 12-month diagnosed prevalent cases of AD in the adult population by severity
• Figure 6: 7MM, sources used to forecast the 12-month diagnosed prevalent cases of AD in the pediatric population by severity
• Figure 7: 7MM, 12-month diagnosed prevalent cases of AD, N, both sexes, all ages, 2023
• Figure 8: 7MM, 12-month diagnosed prevalent cases of AD by age, N, both sexes, 2023
• Figure 9: 7MM, 12-month diagnosed prevalent cases of AD by sex, N, all ages, 2023
• Figure 10: 7MM, 12-month diagnosed prevalent cases of AD by severity, both sexes, N, all ages, 2023

Atopic dermatitis (AD) (International Classification of Diseases, 10th Revision [ICD-10] code L20) is a heterogenous and chronic inflammatory skin condition that is characterized by the remission and relapse of skin lesions and pruritus. Severe AD can impact patients' daily life and cause sleep disturbances, anxiety, depression, and impaired quality of life (QoL) (Kawaguchi et al., 2024; Silverberg et al., 2018).

AD is a complex disease that presents with a range of clinical manifestations and symptoms, depending on the patient demographic and disease severity (Nutten, 2015). The pathogenesis of AD is unclear, and most likely stems from the interaction of a combination of genetic susceptibility, environmental and lifestyle risk factors, and dysfunctional cell-mediated immunity. AD severity ranges from mild to severe. In severe cases, AD is associated with sleep disturbances due to the pruritic rashes that appear on the skin during a flare-up, depression and anxiety, and loss of productively, contributing to the economic and disease burden globally (Laughter et al., 2021). According to the Global Burden of Disease (GBD) database, AD ranks 15th among all nonfatal diseases and has the highest disease burden among skin diseases, as measured by disability-adjusted life-years (DALYs). A positive correlation has been found between a country's gross domestic product (GDP) and disease burden, and while the overall prevalence of AD has remained stable in the last decade, the age distribution of AD is a bimodal curve. The highest prevalence is seen in childhood, followed by the middle-age and older population (Laughter et al., 2021). However, prevalence variation exists depending on age, sex, ethnicity, and socio-economic status, and new epidemiological patterns are slowly emerging, such as AD prevalence increasing in low-income countries and new AD-onset in adults becoming increasingly more common, particularly in the West (Elsawi et al., 2022; Nutten, 2015).

Scope

• This report provides an overview of the severity and the global and historical epidemiological trends for AD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report includes a 10-year epidemiology forecast for the 12-month diagnosed prevalent cases of AD. The 12-month diagnosed prevalent cases of AD are segmented by age (all ages) and sex (men and women). The 12-month diagnosed prevalent cases of AD among men and women are segmented by the severity of disease (mild, moderate, and severe).
• This epidemiology forecast for AD is supported by data obtained from country-specific peer-reviewed articles and population-based studies.
• The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast 12-month diagnosed prevalent cases of AD across these markets.

Reasons to Buy

• Atopic Dermatitis Epidemiology series will allow you to -
• - Develop business strategies by understanding the trends shaping and driving the global atopic dermatitis markets.
• - Quantify patient populations in the global atopic dermatitis markets to improve product design, pricing, and launch plans.
• - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for atopic dermatitis therapeutics in each of the markets covered.
• - Understand magnitude of the atopic dermatitis population by age, sex, and disease severity.

Table of Contents

Table of Contents

• About GlobalData

1 Atopic Dermatitis: Executive Summary

• 1.1 Catalyst
• 1.2 Related reports
• 1.3 Upcoming reports

2 Epidemiology

• 2.1 Disease background
• 2.2 Risk factors and comorbidities
• 2.3 Global and historical trends
• 2.4 7MM forecast methodology
  • 2.4.1 Sources
  • 2.4.2 Forecast assumptions and methods
  • 2.4.3 Forecast assumption and methods: 12-month diagnosed prevalent cases of AD
  • 2.4.4 Forecast assumptions and methods: 12-month diagnosed prevalent cases of AD by severity
• 2.5 Epidemiological forecast for AD (2023-33)
  • 2.5.1 12-month diagnosed prevalent cases of AD
  • 2.5.2 Age-specific 12-month diagnosed prevalent cases of AD
  • 2.5.3 Sex-specific 12-month diagnosed prevalent cases of AD
  • 2.5.4 12-month diagnosed prevalent cases of AD by severity
• 2.6 Discussion
  • 2.6.1 Epidemiological forecast insight
  • 2.6.2 COVID-19 impact
  • 2.6.3 Limitations of the analysis
  • 2.6.4 Strengths of the analysis

3 Appendix

• 3.1 Bibliography
• 3.2 About the Authors
  • 3.2.1 Epidemiologist
  • 3.2.2 Reviewers
  • 3.2.3 Vice President of Disease Intelligence and Epidemiology
  • 3.2.4 Global Head of Pharma Research, Analysis and Competitive Intelligence
• Contact Us